By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Smiths Detection and Novartis Diagnostics have signed a license and collaboration agreement to develop and commercialize Smiths Detection's Bio-Seeq PCR-based instrument and infectious disease diagnostic tests.

Smiths will develop and enhance the Bio-Seeq platform for use in a range of point-of-care diagnostic tests that Novartis Diagnostics will then move through clinical trials, regulatory affairs, and sales and marketing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.